ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

MedImmune And Wuxi Team Up In China

by Jean-François Tremblay
September 17, 2012 | APPEARED IN VOLUME 90, ISSUE 38

MedImmune, the biologics unit of AstraZeneca, and the Chinese R&D contractor WuXi AppTec have agreed to set up a joint venture to conduct clinical trials on, register, and sell one of MedImmune’s drug candidates in China. The candidate, MEDI5117, aimed at treating autoimmune and inflammatory diseases, is currently in Phase I clinical trials in the U.S. and Europe. The joint venture plans to produce MEDI5117 in China because the country’s regulations require domestic manufacturing of a drug candidate that is not already commercially approved in other countries.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment